News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Emphasys Medical Cancels Plans for IPO
May 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (AP) -- Emphasys Medical Inc., which developed a medical device to treat emphysema, has canceled its plans for an initial public offering, citing market conditions, according to a Securities and Exchange Commission filing Monday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor
Business
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
October 7, 2026
·
2 min read
·
Jef Akst
Deals
Shionogi makes $2B rare disease play with IntraBio buy
October 6, 2026
·
2 min read
·
Tristan Manalac
Licensing
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
October 5, 2026
·
2 min read
·
Heather McKenzie